PT  - JOURNAL ARTICLE
AU  - Yann Ehinger
AU  - Ziyang Zhang
AU  - Khanhky Phamluong
AU  - Drishti Soneja
AU  - Kevan M. Shokat
AU  - Dorit Ron
TI  - Brain-Specific Inhibition of mTORC1 by a Dual Drug Strategy: A Novel Approach for the Treatment of Alcohol Use Disorder
AID  - 10.1101/2020.10.12.336701
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.10.12.336701
4099  - http://biorxiv.org/content/early/2020/10/12/2020.10.12.336701.short
4100  - http://biorxiv.org/content/early/2020/10/12/2020.10.12.336701.full
AB  - Alcohol Use Disorder (AUD) is a devastating psychiatric disorder affecting a large portion of the population. Unfortunately, efficacious medications to treat the disease are limited and thus AUD represents an area of unmet medical need. mTORC1 plays a crucial role in neuroadaptations underlying alcohol use. mTORC1 also contributes to alcohol craving, habit, and relapse. Thus, mTORC1 inhibitors are promising therapeutic agents to treat AUD. However, chronic inhibition of mTORC1 in the periphery produces undesirable side effects in humans, which limit their potential clinical use for the treatment of AUD. To overcome these limitations, we utilized a binary drug strategy in which mice were co-administered the mTORC1 inhibitor RapaLink-1 together with a novel small molecule (RapaBlock) to protect mTORC1 activity in the periphery. We show that the dual administration of RapaLink-1 with RapaBlock, abolishes RapaLink-1-dependent mTORC1 inhibition in the liver and blocks adverse side effects detected in humans including body weight loss, glucose intolerance and liver toxicity. Importantly, we show that co-administration of RapaLink-1 and RapaBlock inhibits alcohol-dependent mTORC1 activation in the Nucleus Accumbens and robustly moderates the level of alcohol use. Our data present a novel approach that could be used to treat individuals suffering from AUD.Competing Interest StatementThe authors have declared no competing interest.